US Biosimilar Sponsors Seek Off-The-Record Discussions

Biosimilar Sponsors Want Off-The-Record Labeling Discussions With FDA

 
• By Derrick Gingery
  
Meeting
IP issues often are part of biosimilar labeling carve-out discussions, and could be used in future patent litigation if on the record, sponsors say • Source: Shutterstock

More from Biosimilars

More from Products